Free Access to TSR Screeners - Sign Up for Your Nightly Pass
Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech Charts
Future/OptionFundamental Analysis of Mankind Pharma Ltd. - Growth / Value Index
MANKIND - Valuation Highlights
Valuation Analysis
Tremendous increasing in Book Value last 3 year
Tsr Value Index - Very Poor Score of 11.11
Price to Earning Ratio is 55.18 and EV to EBITDA is 30.68 suggesting that it is very expensive
Price to Book Ratio of 8.66 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 55.18 | 49.20 | 2.12 % | ||
| Price to Book | 8.66 | 6.84 | -30.57 % | 7.28 | |
| Price to Sales | 8.06 | 8.02 | -10.02 % | ||
| Enterprise Value to EBITDA Multiple | 29.80 | -8.79 % |
MANKIND - Profitability Highlights
Profitability Analysis
Company Earning excess return
Piotroski F Score - Stable Value of 5.0
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Good Return on Equity of 16.00% is achieved by the company
Good Net Margin of 14.61% is achieved by the company
Very Low Dividend Yield of 0 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 16.00 | 13.89 | -32.01 % | 3.06 | |
| Return On Asset | 9.92 | 7.17 | -55.15 % | 1.58 | |
| Net Profit Margin | 14.61 | 16.31 | -11.89 % | 12.28 | |
| Operating Profit Margin | 60.17 | 16.12 | -20.81 % | 23.72 | |
| EBITDA Margin | 28.67 | 29.12 | 6.87 % | 25.87 |
Highlights
| Market Cap | 1052.78 B |
| Enterprise Value | 1132.35 B |
| Price/Book TTM | 8.66 |
| Outstanding Share | 412758 K |
| Float/ Outstanding Share | 25.68% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 4.18 |
| Peter Lynch Ratio | 0.058 |
| Piotroski F Score | 5.00 |
| Altman Z Score | 6.16 |
| Sloan Ratio | 0.442 |
| Peter Lynch Fair Value | 852.75 |
MANKIND - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 23.75
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 12956.23 (Cr) | 18.12 % | 15.94 % |
| Gross Profit | 8465.10 (Cr) | 22.36 % | 14.19 % |
| EBITDA | 3715.04 (Cr) | 26.24 % | 0.549 % |
| Net Profit | 1892.79 (Cr) | 4.08 % | 4.17 % |
| EPS | 46.55 | 3.20 % | NA |
MANKIND - Stability Highlights
Stability Analysis
Altman Z Score of 6.19 suggests good Stability
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.594 | 2583.96 % | 0.207 | |
| Cash Ratio | 0.098 | -94.02 % | ||
| Quick Ratio | 0.898 | -62.67 % | 0.864 | |
| Shareholders Equity | 51.63 | -34.03 % | ||
| Debt to EBITDA | 2.39 | 3154.54 % |
Historical Valuation Ratios of Mankind Pharma Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Mankind Pharma Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Mankind Pharma Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Mankind Pharma Ltd.
Historical Solvency Ratios
Loading ...